Nonbismuth concomitant quadruple therapy for *Helicobacter pylori* eradication in Chinese regions: A meta-analysis of randomized controlled trials

Lien-Chieh Lin, Tzu-Herng Hsu, Kuang-Wei Huang, Ka-Wai Tam

**AIM:** To evaluate the applicability of nonbismuth concomitant quadruple therapy for *Helicobacter pylori* (*H. pylori*) eradication in Chinese regions.

**METHODS:** A systematic review and meta-analysis of randomized controlled trials was performed to evaluate the efficacy of nonbismuth concomitant quadruple therapy between sequential therapy or triple therapy for *H. pylori* eradication in Chinese regions. The defined Chinese regions include China, Hong Kong, Taiwan, and Singapore. The primary outcome was the *H. pylori* eradication rate; the secondary outcome was the compliance with therapy. The PubMed, Embase, Scopus, and Cochrane databases were searched for studies published in the period up to March 2016 with no language restriction.

**RESULTS:** We reviewed six randomized controlled trials and 1616 patients. In 3 trials comparing concomitant quadruple therapy with triple therapy, the *H. pylori* eradication rate was significantly higher for 7-d
nonbismuth concomitant quadruple therapy than for 7-d triple therapy (91.2% vs 77.9%, risk ratio = 1.17, 95%CI: 1.09-1.25). In 3 trials comparing quadruple therapy with sequential therapy, the eradication rate was not significant between groups (86.9% vs 86.0%). However, higher compliance was achieved with concomitant therapy than with sequential therapy.

CONCLUSION: The *H. pylori* eradication rate was higher for nonbismuth concomitant quadruple therapy than for triple therapy. Moreover, higher compliance was achieved with nonbismuth concomitant quadruple therapy than with sequential therapy. Thus, nonbismuth concomitant quadruple therapy should be the first-line treatment in Chinese regions.

Key words: *Helicobacter pylori* eradication; Nonbismuth concomitant quadruple therapy; Peptic ulcer; Chinese region

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: *Helicobacter pylori* (H. pylori) infection is highly prevalent in Chinese regions and associated with peptic ulcers. Currently, triple and sequential therapies have been widely used to eradicate *H. pylori*. Nonbismuth concomitant quadruple therapy is an alternative treatment with high efficacy. Our meta-analysis revealed that a higher *H. pylori* eradication rate was achieved with 7-d concomitant therapy than with 7-d triple therapy. The eradication rates of concomitant and sequential therapies were similar. However, the compliance with concomitant therapy was higher. Therefore, nonbismuth concomitant quadruple therapy should be the first-line treatment for *H. pylori* infection.

By contrast, studies have shown a high eradication rate for sequential therapy, which entails administering a PPI and amoxicillin for 5 d, followed by a PPI, clarithromycin, and metronidazole (or tinidazole) for another 5 d. However, compliance may be poor because of the complexity of sequential therapy and the high eradication rate. In addition, nonbismuth concomitant quadruple therapy, involving the simultaneous administration of a PPI, amoxicillin, clarithromycin, and metronidazole for 7 or 10 d, is more convenient than sequential therapy, although its efficacy remains to be determined.

Peptic ulcer is a common disease in Chinese regions. In Taiwan, the overall prevalence of *H. pylori* infection is 54%, and it increases with age. However, the infection rate of *H. pylori* is only 31% in Singapore. Because antibiotic resistance is a critical reason for *H. pylori* eradication failure, studies on *H. pylori* eradication are needed within specific regions. However, most meta-analyses of *H. pylori* eradication have been performed in Europe and Korea, and the optimal treatment for *H. pylori* eradication in Chinese regions is still unknown. Therefore, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate whether nonbismuth concomitant quadruple therapy is the first-line therapy for *H. pylori* eradication in Chinese regions.

MATERIALS AND METHODS

Data sources

The PubMed, Embase, Scopus, and Cochrane databases were searched for studies published in the period up to March 2016 without language restrictions. The following medical search heading terms, words, and combinations of words were used in the systematic search: *Helicobacter pylori* or *H. pylori*, eradication, peptic or gastric or duodenal ulcer, concomitant or quadruple, and China or Chinese or Hong Kong or Taiwan or Singapore. All included studies were also entered into the PubMed “similar articles” function and the science citation index. Moreover, we identified additional studies by manually searching the reference sections of these papers and by contacting known experts in the field. Finally, unpublished trials were retrieved from the ClinicalTrials.gov registry (http://clinicaltrials.gov/). The systematic review described herein was accepted by the online PROSPERO international prospective register of systematic reviews of the National Institute for Health Research (CRD42016-032668).

Study selection

The following studies were selected for analysis: RCTs evaluating the efficacy of nonbismuth concomitant quadruple therapy versus standard triple or sequential for *H. pylori* eradication; those performed in Chinese regions including China, Hong Kong, Taiwan, and Singapore; patients aged 18 years or over; those

INTRODUCTION

*Helicobacter pylori* (H. pylori) infection has been proven to be the major cause of chronic gastritis, gastric and duodenal ulcers, gastric adenocarcinoma, and gastric mucosa-associated lymphoma. Moreover, *H. pylori* eradication has become the standard and most widely adopted therapy for curing peptic ulcers. According to most international guidelines, conventional triple therapy, involving the use of a proton pump inhibitor (PPI) with amoxicillin and clarithromycin for 7-10 d, is the first-line therapy for *H. pylori* eradication. However, the eradication rate of triple therapy has decreased to 80% in many countries worldwide.
Data extraction and quality assessment
Two independent reviewers (Lin LC and Hsu TH) extracted the data of the trials, including the participants, inclusion and exclusion criteria, administration of experimental drugs, prevalence and assessment of H. pylori infection, and complications. Discrepancies and any disagreements were resolved through discussion with a third reviewer (Tam KW). The authors of the studies were contacted for additional information when necessary.

The risk of bias in the included trials was assessed using the following domains: adequacy of the randomization, allocation concealment, blinding, duration of follow-up, numbers of drop-outs, and performance of intention-to-treat (ITT) analysis.

Data synthesis and analysis
The H. pylori eradication rate was the primary outcome used to evaluate the efficacy of nonbismuth concomitant quadruple therapy. The occurrence of H. pylori infection was determined using assessments of histology, culture, rapid urease tests, or breath tests. The secondary outcome was the compliance with treatment.

The analysis was performed using the statistical package Review Manager, version 5.3 (Cochrane Collaboration, Oxford, England). The meta-analysis was performed according to the recommendations of the PRISMA statement[31]. For dichotomous data, the results were summarized as risk ratios (RRs) with 95% CIs. A pooled estimate of the RR was calculated using the DerSimonian and Laird random effect model[32]. This approach provides a more appropriate estimate of the average treatment effect when trials are statistically heterogeneous and usually yields wider CIs, thereby resulting in a more conservative statistical claim. \( \chi^2 \) statistics tests (Q statistics) and the \( I^2 \) test were used to test for heterogeneity among controlled trials.

RESULTS
Characteristics of the trials
The review process is outlined in Figure 1. The initial search yielded 990 studies, 567 of which were deemed ineligible through screening of titles and abstracts. Subsequently, the full text of 423 studies was screened. Of these, five did not meet the eligibility criteria because of duplicate publication, 18 were not randomized studies, 71 evaluated H. pylori eradication in different regions, and 323 included different comparisons. Thus, only six eligible trials were included in this meta-analysis[20,22,33-36].

The main characteristics of the studies are listed in Table 1. Four of the six studies were performed in Taiwan, and the remaining two were conducted in China and Singapore. The publication dates of the studies were between 2012 and 2015, and the sample sizes ranged from 169 to 462. All trials evaluated patients diagnosed with H. pylori infection. In our included studies, three indicated that their patients had gastritis or peptic ulcers[33-35]. Only one study did not report the tests for diagnosing H. pylori infection[34], and other studies reported the following diagnostic tests: rapid urease test, histology, urea breath test, and culture. The timing of evaluation for the H. pylori infection status ranged from 4 to 12 wk after the treatment course. Treatment strategies for H. pylori eradication varied among the studies. Regarding the PPIs administered, three studies used esomeprazole[20,34,35], one used pantoprazole[33], one used lansoprazole[22], and one...
Table 1 Characteristics of included studies

| Ref. | Inclusion criteria | Region | Diagnostic test | No. of patients (male %) | Age, yr (mean ± SD) | Intervention |
|------|-------------------|--------|-----------------|--------------------------|---------------------|--------------|
| Ang et al (2015) | Age ≥ 21 yr | Singapore | RUT, H, UBT | C10 | 153 (47.1) | S10: 154 (59.7) | 10-d concomitant therapy |
| | | | | T10 | 155 (58.1) | T10: 49.8 ± 14.6 | 10-d sequential therapy |
| Hsu et al (2014) | Age ≥ 20 yr, PU or gastritis | Taiwan | RUT, Cu, H | C7: 102 (59.8) | S7: 102 (50.9) | 7-d concomitant therapy |
| | | | | T7: 103 (60.2) | T7: 56.1 ± 14.0 | 7-d sequential therapy |
| Huang et al (2012) | Dyspepsia or epigastric discomfort | Taiwan | RUT, Cu, H | C10: 84 (57.1) | S10: 85 (56.7) | 10-d concomitant therapy |
| | | | | T7: 92 (49.0) | T7: 52.8±12.8 | 7-d sequential therapy |
| Tai et al (2015) | Age ≥ 20 yr, PU or gastritis | Taiwan | Not reported | C7: 92 (50.0) | S7: 92 (49.0) | 7-d concomitant therapy |
| | | | | T7: 82 (42.7) | T7: 51 ± 15 | 7-d sequential therapy |
| Wang et al (2014) | PU and gastritis | China | UBT | C7: 81 (45.7) | S7: 83 (45.8) | 10-d sequential therapy |
| | | | | T7: 72 (40.2) | T7: 50 ± 14 | 7-d sequential therapy |
| Wu et al (2010) | Patients visited GI clinics with HP infection | Taiwan | RUT, Cu, H | C10: 115 (52.2) | S10: 117 (52.1) | 10-d sequential therapy |
| | | | | T7: 82 (51.8) | T7: 51 ± 12 | 7-d sequential therapy |

Concomitant therapy: PPI, amoxicillin, clarithromycin, and metronidazole for 7-10 d; sequential therapy: PPI and amoxicillin for 5 d, followed by PPT, clarithromycin, and metronidazole (or tinidazole) for 7 d; triple therapy: PPI, amoxicillin, and clarithromycin for 7-10 d. PPI: lansoprazole, pantoprazole, or esomeprazole; GI: Gastrointestinal; PU: Peptic ulcer; C7: 7-d concomitant therapy; S10: 10-d concomitant therapy; T7: 7-d triple therapy; T10: 10-d triple therapy; Cu: Culture; H: Histology; RUT: Rapid urease test; UBT: Urea breath test.

H. pylori eradication rate

Nonbismuth concomitant quadruple therapy vs triple therapy: Three studies compared the H. pylori eradication rates of 7-d nonbismuth concomitant quadruple and triple therapies[^36]. The timing of H. pylori infection status assessment was 4 wk after treatment. No significant difference was observed in the overall H. pylori eradication rates of nonbismuth concomitant quadruple and triple therapies (81.7% vs 83.2%, RR = 0.98, 95%CI: 0.89-1.09) (Figure 2). Fewer patients receiving nonbismuth concomitant quadruple therapy experienced H. pylori infection after treatment (RR = 1.17, 95%CI: 1.09-1.25) (Figure 2). The results demonstrated low heterogeneity among the studies (I² = 0%).

One study compared the H. pylori eradication rates of 10-d nonbismuth concomitant quadruple and triple therapies[^36]. The timing of H. pylori infection status assessment was 4 wk after treatment. No significant difference was observed in the H. pylori eradication rates of nonbismuth concomitant quadruple and triple therapies (81.7% vs 83.2%, RR = 0.98, 95%CI: 0.89-1.09) (Figure 2).

Nonbismuth concomitant quadruple therapy vs sequential therapy: Three studies compared the H. pylori eradication rate of 10-d nonbismuth concomitant quadruple and sequential therapies[^20,22,36]. The timing of H. pylori infection status assessment was different among the studies: 4 wk[^36], 6 wk[^20], and 12 wk[^22] after treatment. No statistically significant difference was observed in the overall H. pylori eradication rates of nonbismuth concomitant quadruple and sequential therapies (86.9% vs 86.0%, RR = 1.01, 95%CI: 0.95-1.07) (Figure 2).

Compliance

Nonbismuth concomitant quadruple therapy vs triple therapy: Three studies compared the compliance with 7-d nonbismuth concomitant quadruple and triple therapies[^33-35]. No statistically significant difference was observed in the compliance with these therapies (100% vs 99.3%, RR = 1.01, 95%CI: 0.99-1.02) (Figure 3).

Nonbismuth concomitant quadruple therapy vs sequential therapy: Three studies compared the...
### Table 2  Assessment of methodological quality of included studies

| Ref.          | Region     | Allocation generation | Allocation concealment | Blinding of patients and assessors | Data analysis | Loss to follow up | Selective reporting | Other bias                                      |
|---------------|------------|------------------------|------------------------|------------------------------------|---------------|------------------|--------------------|-----------------------------------------------|
| Ang et al[36] (2015) | Singapore | Sealed envelope         | Adequate               | Open-label                         | ITT/PP        | 10.0%            | Low risk            | Not all patients underwent antibiotic susceptibility testing |
| Hsu et al[33] (2014)     | Taiwan    | Computer generated     | Adequate               | Open-label                         | ITT/PP        | 0.3%             | Low risk            | Not all patients underwent antibiotic susceptibility testing |
| Huang et al[22] (2012)  | Taiwan    | Computer generated     | Unclear                | Open-label                         | ITT/PP        | 6.5%             | Low risk            | No patient underwent antibiotic susceptibility testing |
| Tai et al[34] (2015)     | Taiwan    | Computer generated     | Adequate               | Unclear                            | ITT/PP        | 8.0%             | Low risk            | Not all patients underwent antibiotic susceptibility testing |
| Wang et al[35] (2014)    | Taiwan    | Computer generated     | Unclear                | Outcome assessor blinded           | ITT/PP        | 0.4%             | Low risk            | No patient underwent antibiotic susceptibility testing |
| Wu et al[20] (2010)      | Taiwan    | Computer generated     | Unclear                |                                    | ITT/PP        |                  |                    |                                                               |

Risk of bias was assessed according to the method recommended by the Cochrane Collaboration. ITT: Intention-to-treat; PP: Per-protocol.

### Figure 2  Forest plot for comparison of concomitant quadruple therapy with other therapies.

Outcome: *Helicobacter pylori* eradication rate.
the compliance with 10-d nonbismuth concomitant quadruple and sequential therapies[20,22,36]. Although no significant difference was observed in the compliance with these therapies (97.5% vs 95.0%, RR = 1.03, 95%CI: 1.00-1.06), more patients tended to comply with nonbismuth concomitant quadruple therapy (Figure 3).

Adverse events
Two studies compared adverse events including abdominal pain, gastrointestinal disturbance, nausea and vomiting, skin rash, dizziness, fatigue between 10-d nonbismuth concomitant quadruple and sequential therapies[20,22]. Patients receiving these two therapies showed a similar adverse event rate. Moreover, three studies compared the adverse event rate between 7-d nonbismuth concomitant quadruple and triple therapies[32-35]. Among two studies, patients receiving these two therapies showed a similar incidence of adverse events[33,35]. One study reported more adverse events after 7-d nonbismuth concomitant quadruple therapy than after triple therapy[34]. However, these effects were mild and did not markedly interfere with the patients’ daily activities.

DISCUSSION
Because antibiotic resistance is a critical reason for H. pylori eradication failure, we conducted a systematic review and meta-analysis of RCTs to evaluate whether nonbismuth concomitant quadruple therapy is the optimal first-line therapy for H. pylori eradication in Chinese regions. Our meta-analysis revealed that a higher H. pylori eradication rate was achieved with 7-d concomitant therapy than with 7-d triple therapy. The eradication rates of concomitant and sequential therapies were similar. However, the compliance with concomitant therapy was higher. Therefore, nonbismuth concomitant quadruple therapy should be the first-line treatment for H. pylori infection.

Recently, Li et al[37] conducted a network meta-analysis of treatment for H. pylori infection. They showed that nonbismuth concomitant quadruple treatment is effective in H. pylori eradication. However, ethnicity and region play pivotal roles in antibacterial treatments; thus, investigating H. pylori eradication in different regions is necessary[38]. In South Korea, two RCTs showed that a much higher H. pylori eradication rate was achieved with nonbismuth concomitant quadruple therapy than with standard triple therapy or sequential therapy[26,39]. In Japan, an RCT also reported a higher eradication rate for nonbismuth concomitant quadruple therapy than that for triple therapy[40]. Our study revealed a similar outcome in Chinese regions.

Although the included studies used different PPIs, the same PPI was administered to the experimental groups in all studies, except for Ang et al[36]. Nevertheless, a meta-analysis revealed that different PPI types did not have different efficacies for H. pylori eradication[41]. Moreover, regarding concomitant therapy, Wang et al[35] substituted metronidazole with tinidazole; the eradication rate of that study is similar to that of other studies using metronidazole. These results are compatible with the trial that compared the efficacy of tinidazole and metronidazole for H. pylori eradication[42].

The optimal dosage of metronidazole remains undetermined. All RCTs used 500 mg of metronidazole twice daily, except for Ang et al[36], who used 400 mg twice daily. Nevertheless, Ang et al[36] still obtained a high eradication rate; this finding indicated that metronidazole doses from 400 to 500 mg are acceptable for H. pylori eradication.
**Helicobacter pylori** eradication.

To determine the effectiveness of the treatments in practice, we considered the compliance rate. Although the eradication rates of nonbismuth concomitant and sequential therapies were not statistically different, higher compliance was achieved with nonbismuth concomitant therapy than with sequential therapy. Generally, the compliance rate may be higher in RCTs than in clinical settings. Thus, nonbismuth concomitant therapy may be a superior choice for **H. pylori** eradication because higher compliance was achieved with this therapy than with sequential therapy.

The value of $I^2$ was 0%-14% for each therapy, revealed that mild heterogeneity existed among our selected studies. This could be attributed to heterogeneity among patients’ demographics and characteristics and the inclusion and exclusion criteria, dose and route of administration of **H. pylori** treatment, and time of outcome assessment.

Our study has several limitations. First, all our studies were open label, except for the study of Wu et al.[20], which was outcome assessor blinded. However, we believe that this is not a major concern because the treatment outcomes were mainly objective. Second, not all trials evaluate antibiotic susceptibility. Third, because China has the highest population globally, more RCTs conducted in China may be required to determine the optimal treatment for **H. pylori** infection in Chinese regions.

In conclusion, the evidence reviewed in the present meta-analysis indicated that nonbismuth concomitant quadruple therapy achieved a higher **H. pylori** eradication rate than that of standard triple therapy and higher compliance than that of sequential therapy. Therefore, nonbismuth concomitant quadruple therapy should be the first-line treatment for **H. pylori** infection in Chinese regions.

**COMMENTS**

**Background**

Peptic ulcer is a common disease in Chinese regions, and Helicobacter pylori (**H. pylori**) eradication has become the standard and most widely adopted therapy. However, eradication rate of standard triple therapy has decreased to 80% in many countries worldwide, and compliance of sequential therapy may be poor due to the complexity. Therefore, there is a need to evaluate whether nonbismuth concomitant quadruple therapy is the first-line therapy for **H. pylori** eradication in Chinese regions.

**Research frontiers**

Due to increasing antibiotic resistance, current **H. pylori** eradication therapies may be poor. In this study, the authors compared eradication rate and compliance rate of three different types of therapies in Chinese region.

**Innovations and breakthroughs**

This study is the first meta-analysis to compare nonbismuth concomitant quadruple therapy with triple therapy and sequential therapy in Chinese region. Based on this study, nonbismuth concomitant quadruple therapy showed high **H. pylori** eradication rate and good compliance rate in Chinese region.

**Applications**

This study showed high efficacy and compliance in nonbismuth concomitant quadruple therapy. Thus, nonbismuth concomitant quadruple therapy is a good choice for first-line **H. pylori** eradication therapy in Chinese region.

**Terminology**

Nonbismuth concomitant quadruple therapy consist of proton pump inhibitor plus amoxicillin, clarithromycin, and nitromidazole derivatives given for 7-14 d. Chinese regions in this study included China, Hong Kong, Taiwan, and Singapore.

**Peer-review**

The results of this meta-analysis showed that treatment with nonbismuth concomitant quadruple therapy resulted in high **H. pylori** eradication rate in Chinese region. In addition, good compliance rate and mild adverse effects were also noted in this study. Consequently, the study provided a better choice for first-line eradication therapy of **H. pylori** in Chinese region.

**REFERENCES**

1. Suerbaum S, Michetti P. Helicobacter pylori infection. *N Engl J Med* 2002; 347: 1175-1186 [PMID: 12374879 DOI: 10.1056/NEJMra020542]

2. Malfertheiner P, Chen FK, McColl KE. Peptic ulcer disease. *Lancet* 2009; 374: 1449-1461 [PMID: 19683340 DOI: S0140-6736(09)60938-7]

3. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. *Gastroenterology* 2009; 137: 1641-1648.e1-2 [PMID: 19664631 DOI: 10.1053/j.gastro.2009.07.060]

4. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ, Saeed ZA, Malaty HM. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. *Ann Intern Med* 1992; 116: 705-708 [PMID: 1558340 DOI: 10.7326/0003-4819-116-9-705]

5. Sung JJ, Chung SC, Ling TK, Yung MY, Leung VK, Ng EK, Li MK, Cheng AF, Li HP. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. *N Engl J Med* 1995; 332: 139-142 [PMID: 7800005 DOI: 10.1056/NEJM19950133203020]

6. Wong CS, Chia CF, Lee HC, Wei PL, Ma HP, Tsai SH, Wu CH, Tam KW. Eradication of Helicobacter pylori for prevention of ulcer recurrence after simple closure of perforated peptic ulcer: a meta-analysis of randomized controlled trials. *J Surg Res* 2013; 182: 219-226 [PMID: 23158404 DOI: 10.1016/j.jss.2012.10.046]

7. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley N, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA; Second Asia-Pacific Conference. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. *J Gastroenterol Hepatol* 2009; 24: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.09582.x]

8. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, Uemura N, Murakami K, Satoh K, Sugano K; Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. *Helicobacter* 2010; 15: 1-20 [PMID: 20302585 DOI: 10.1111/j.1523-5378.2009.00738.x]

9. Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omari EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection—the Maastricht IV/Florence Consensus Report. *Gut* 2012; 61: 646-664 [PMID: 22491490 DOI: 10.1136/gutjnl-2012-302884]

10. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 2007; 102: 1808-1825 [PMID: 17698976 DOI: 10.1111/j.1523-5378.2007.00738.x]
Effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2007; 26: 343-357 [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x]

Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, Ripani C, Tomassini G, Attili AF. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2000; 14: 715-718 [PMID: 10848654 DOI: 10.1046/j.1365-2036.2000.00766.x]

Essa AS, Kramer JR, Graham DY, Trieber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. *Helicobacter* 2009; 14: 109-118 [PMID: 19298338 DOI: 10.1111/j.1572-922X.2009.00671.x]

Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. *Ann Intern Med* 2008; 148: 923-931 [PMID: 18490667 DOI: 10.7326/0003-4819-148-12-200806170-00226]

Wu DC, Hsu PI, Wu JY, Opekun AR, Chuah SK, Lee CH, Liang CM, Lu LS, Kuo YH, Yen YH. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. *Antimicrob Agents Chemother* 2014; 58: 5936-5942 [PMID: 25070099 DOI: 10.1128/AAC.02922-14]

Tai WC, Liang CM, Lee CH, Chu IH, Yu ML, Lu LS, Kuo YH, Kuo CM, Yen YH, Kuo CH, Chiuou SS, Wu KL, Chiu YC, Hu TH, Chuah SK. Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication. *Biomed Res Int* 2015; 2015: 623732 [PMID: 26009428]

Wang S, Wang W, Chu Y, Teng G, Hu F. [Non-bismuth quadruple therapy versus standard triple therapy for Helicobacter pylori eradication: a randomized controlled study]. *Zhonghua Yi Xue Za Zhi* 2014; 94: 576-579 [PMID: 24762684]

Ang TL, Fock KM, Song M, Ang D, Kwek AB, Ong J, Tan J, Teo EK, Dhamdhar S. Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection. *J Gastroenterol Hepatol* 2015; 30: 1134-1139 [PMID: 25639278 DOI: 10.1111/jgh.12892]

Li BZ, Threapleton DE, Wang JY, Xu JM, Yuan JQ, Zhang C, Li P, Ye QL, Guo B, Mao C, Ye DQ. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. *BMJ* 2015; 351: h4052 [PMID: 26290044 DOI: 10.1136/bmj.h4052]

Wu IT, Chuah SK, Lee CH, Liang CM, Lu LS, Kuo YH, Yen YH, Hu ML, Chou YP, Yang SC, Kuo CM, Kuo CH, Chien CC, Chiang YS, Chio Su HS, Hu TH, Tai WC. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. *World J Gastroenterol* 2015; 21: 10669-10674 [PMID: 26457027 DOI: 10.3748/wjg.v21.i47.10669]
eradication rate for Helicobacter pylori among various treatment strategies. *World J Gastroenterol* 2015; **21**: 351-359 [PMID: 25574111 DOI: 10.3748/wjg.v21.i1.351]

40 Nagahara A, Miwa H, Yamada T, Kurosawa A, Ohkura R, Sato N. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. *Aliment Pharmacol Ther* 2001; **15**: 417-421 [PMID: 11207518 DOI: 10.1046/j.1365-2036.2001.00929.x]

41 Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. *Aliment Pharmacol Ther* 2003; **18**: 647-654 [PMID: 12969092 DOI: 10.1046/j.1365-2036.2003.01746.x]

42 Berruti M, Pellicano R, Astegiano M, Smedile A, Saracco G, Morgando A, De Angelis C, Repici A, Fagoonee S, Leone N, Rizzetto M. Helicobacter pylori eradication: metronidazole or tinidazole? Data from Turin, Italy. *Minerva Gastroenterol Dietol* 2008; **54**: 355-358 [PMID: 19047976]

P- Reviewer: Slomiany BL, Tovey FI S- Editor: Gong ZM L- Editor: AE- Editor: Ma S
